Glycemic variability and cardiovascular disease in patients with type 2 diabetes

Glycemic variability and cardiovascular disease in patients with type 2 diabetes

Glycated hemoglobin is currently the gold standard for assessment of long-term glycemic control and response to medical treatment in patients with diabetes. Glycated hemoglobin, however, does not address fluctuations in blood glucose. Glycemic variability (GV) refers to fluctuations in blood glucose...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open diabetes research & care Vol. 9; no. 1; p. e002032
Main Authors: Martinez, Marcela, Santamarina, Jimena, Pavesi, Adrian, Musso, Carla, Umpierrez, Guillermo E
Format: Journal Article
Language:English
Published: England BMJ Publishing Group LTD 24-03-2021
BMJ Publishing Group
Subjects:
Cardiovascular and Metabolic Risk
Cardiovascular disease
Clinical medicine
Diabetes
Glucose monitoring
Hyperglycemia
Hypoglycemia
Life expectancy
Medical diagnosis
Mortality
Patients
diagnostic techniques and procedures
cardiovascular system
diabetes mellitus
type 2
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glycated hemoglobin is currently the gold standard for assessment of long-term glycemic control and response to medical treatment in patients with diabetes. Glycated hemoglobin, however, does not address fluctuations in blood glucose. Glycemic variability (GV) refers to fluctuations in blood glucose levels. Recent clinical data indicate that GV is associated with increased risk of hypoglycemia, microvascular and macrovascular complications, and mortality in patients with diabetes, independently of glycated hemoglobin level. The use of continuous glucose monitoring devices has markedly improved the assessment of GV in clinical practice and facilitated the assessment of GV as well as hypoglycemia and hyperglycemia events in patients with diabetes. We review current concepts on the definition and assessment of GV and its association with cardiovascular complications in patients with type 2 diabetes.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2052-4897
2052-4897
DOI:10.1136/bmjdrc-2020-002032